What is Atara Biotherapeutics Inc (ATRA) stock price today?

Atara Biotherapeutics Inc (ATRA) currently trades at $4.77 per share. The stock has a market capitalization of $40.97M and a P/E ratio of 1.95x.

Is ATRA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Atara Biotherapeutics Inc has a Smart Value Score of 34/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is the ATRA stock price target for 2026?

WallStSmart's 12-month price target for Atara Biotherapeutics Inc is $4.96.

What is Atara Biotherapeutics Inc's revenue and earnings?

Atara Biotherapeutics Inc has trailing twelve-month (TTM) revenue of $120.77M with profit margins of 27.10%. Earnings per share (EPS) is $2.57.

ATRA

Atara Biotherapeutics Inc

NASDAQ: ATRA · HEALTHCARE · BIOTECHNOLOGY

$4.77

+3.70% today

Updated 2026-04-30

Market cap

$40.97M

P/E ratio

1.95

P/S ratio

0.34x

EPS (TTM)

$2.57

Dividend yield

—

52W range

$4 – $19

Volume

0.3M

Market cap

$40.97M

P/E ratio

1.95

P/S ratio

0.34x

EPS (TTM)

$2.57

Dividend yield

—

52W range

$4 – $19

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

6.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$9.33

+95.60%

12-Month target

$4.96

+3.98%

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy2 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Profit margin 27.10% — above average

Risks

- Negative free cash flow $-5.70M

- Revenue declining -95.10% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$63.57M	$8.57M	$128.94M	$120.77M	$120.77M
Net income	$-228.30M	$-276.13M	$-85.40M	$32.69M	$-3.41M
EPS	—	—	—	—	$2.57
Free cash flow	$-274.62M	$-194.20M	$-68.96M	$-50.94M	$-5.70M
Profit margin	-359.12%	-3,220.88%	-66.23%	27.07%	27.10%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ATRA	$40.97M	34	5.3	6.0	6.7	5.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Atara Biotherapeutics Inc trades at $4.77. representing a P/E of 1.95x trailing earnings. Our Smart Value Score of 34/100 indicates the stock is weak. TTM revenue stands at $120.77M. with profit margins at 27.10%.

Frequently asked questions

What is Atara Biotherapeutics Inc's stock price?

Atara Biotherapeutics Inc (ATRA) trades at $4.77.

Is Atara Biotherapeutics Inc overvalued?

Smart Value Score 34/100 (Grade F, Strong Sell).

What is the price target of Atara Biotherapeutics Inc (ATRA)?

The analyst target price is $9.33, representing +95.6% upside from the current price of $4.77.

What is Atara Biotherapeutics Inc's revenue?

TTM revenue is $120.77M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio0.34x

ROE-2,015.00%

Beta-0.33

50D MA$5.06

200D MA$10.49

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ATRA vs LLY →ATRA vs JNJ →ATRA vs ABBV →Stock screener →